81. Congenital adrenal hyperplasia Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 87 Drugs : 87 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68

Drugs and their primary sponsors and trial info
AAV BBP-631   
   Adrenas Therapeutics Inc
      2021   Phase 1/Phase 2   NCT04783181   Australia;United States;
ATR-101   
   Millendo Therapeutics US, Inc.
      2018   Phase 2   EUCTR2017-004878-34-ES   Brazil;France;Israel;Spain;
   Millendo Therapeutics, Inc.
      2018   Phase 2   EUCTR2017-004878-34-FR   Brazil;France;Israel;Spain;
      2016   Phase 2   NCT02804178   United States;
Abiraterone acetate   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2011   Phase 1   NCT01495910   United States;
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States;
      2017   Phase 1   NCT02574910   United States;
Bone balance measurements   
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France;
CI-984, 17AA70, PD 132301-2   
   Millendo Therapeutics US, Inc.
      2018   Phase 2   EUCTR2017-004878-34-ES   Brazil;France;Israel;Spain;
   Millendo Therapeutics, Inc.
      2018   Phase 2   EUCTR2017-004878-34-FR   Brazil;France;Israel;Spain;
Chronocort   
   Diurnal Limited
      2021   Phase 3   NCT05063994   United States;
      2011   Phase 1   NCT03051893   -
      2010   Phase 1   NCT03019614   -
      2007   Phase 1/Phase 2   NCT00519818   United States;
      -   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States;
Chronocort®   
   Diurnal Limited
      2018   Phase 3   NCT03532022   United States;
      2016   Phase 3   NCT02716818   United States;
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)   
   Federico II University
      2016   Phase 4   NCT03760835   Italy;
Cortef   
   Diurnal Limited
      2021   Phase 3   NCT05063994   United States;
      2007   Phase 1/Phase 2   NCT00519818   United States;
Cortisol   
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Cortison   
   Haukeland University Hospital
      2012   -   EUCTR2011-005822-23-NO   Norway;
Cortisone acetate   
   Haukeland University Hospital
      2013   Phase 2   NCT01771328   Norway;
Crinecerfont   
   Neurocrine Biosciences
      2021   Phase 3   NCT04806451   Canada;France;Greece;Poland;United States;
      2020   Phase 3   NCT04490915   Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-GR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-FR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-ES   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-DE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2019-004873-17-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004873-17-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004873-17-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-PT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-GR   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004381-19-PL   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      -   Phase 3   EUCTR2020-004381-19-BE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.   
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-IT   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2020   Phase 3   EUCTR2019-004873-17-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
DIURF-006   
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dectancyl   
   Hospices Civils de Lyon
      2015   -   EUCTR2015-003996-32-FR   France;
Dexamethasone   
   Boston Children’s Hospital
      2008   Phase 2   NCT00621985   United States;
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China;
Dexamethasone 0,1 mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 0.5mg Tablet   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 1,5 mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 2mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dual release hydrocortisone (plenadren)   
   Federico II University
      2016   Phase 4   NCT03760835   Italy;
Efmody 10 mg modified release hard capsules   
   Diurnal Limited
      -   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States;
Efmody 5 mg modified release hard capsules   
   Diurnal Limited
      -   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States;
Fludrocortisone   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 2   NCT00001521   United States;
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States;
Flutamide   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 2   NCT00001521   United States;
HYDROCORTISONE MICRONIZED   
   Diurnal Limited
      -   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States;
HYDROCORTISONE SODIUM SUCCINATE   
   Haukeland University Hospital
      2014   Phase 2   EUCTR2011-005822-23-SE   Norway;Sweden;
HYDROCORTISONE- hydrocortisone tablet   
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Hormonal balance measurements   
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France;
Hydrocortisone   
   Boston Children’s Hospital
      2008   Phase 2   NCT00621985   United States;
   Diurnal Limited
      2016   Phase 3   NCT03062280   United States;
      2010   Phase 1   NCT03019614   -
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 2   NCT00001521   United States;
   Fujii Katsuya
      2022   Phase 2   JPRN-jRCT2031210491   France;Japan;Turkey;US;
   Haukeland University Hospital
      2013   Phase 2   NCT01771328   Norway;
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China;
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States;
Hydrocortisone (Solucortef)   
   National Institutes of Health Clinical Center (CC)
      2013   Phase 2   NCT01859312   United States;
Hydrocortisone 10mg Tablet   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 10mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 20mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone Modified Release Capsules   
   Diurnal Limited
      2012   Phase 2   NCT01735617   United States;
Hydrocortisone sodium acetate   
   Baylor College of Medicine
      2007   -   NCT00529841   United States;
Hydrocortisone sodium phosphate   
   University Hospitals Bristol NHS Foundation Trust
      2014   -   EUCTR2012-001104-37-GB   United Kingdom;
Hydrocortisone tablet   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone withdrawal   
   Maria I. New
      2007   -   NCT00542841   Brazil;France;United States;
IDROCORTISONE   
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Infacort   
   Diurnal Limited
      2015   Phase 3   EUCTR2015-000458-40-DE   Germany;
      2015   Phase 3   EUCTR2014-002265-30-DE   Germany;
Infacort®   
   Diurnal Limited
      2016   Phase 3   NCT02733367   Germany;
Insulin pump (Medtronic)   
   National Institutes of Health Clinical Center (CC)
      2013   Phase 2   NCT01859312   United States;
Letrozole   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 2   NCT00001521   United States;
METFORMIN HYDROCHLORIDE   
   Ghent University Hospital
      2014   Phase 3   EUCTR2013-002395-40-BE   Belgium;
Metabolic balance measurements   
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France;
Metformine Sandoz 850 mg filmomhulde tabletten   
   Ghent University Hospital
      2014   Phase 3   EUCTR2013-002395-40-BE   Belgium;
NBI-74788   
   Neurocrine Biosciences
      2019   Phase 2   NCT04045145   United States;
      2018   Phase 2   NCT03525886   United States;
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-IT   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-GR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-FR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-ES   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2020-004381-19-DE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      2021   Phase 3   EUCTR2019-004873-17-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004873-17-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004873-17-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-PT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-GR   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004873-17-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004381-19-PL   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
      -   Phase 3   EUCTR2020-004381-19-BE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
NBI-77860   
   Neurocrine Biosciences
      2015   Phase 1   NCT02349503   United States;
National Drug Code: 59762-0074   
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Nevanimibe hydrochloride   
   Millendo Therapeutics US, Inc.
      2018   Phase 2   NCT03669549   Brazil;Czechia;France;Israel;Spain;
Nifedipine   
   National Center for Research Resources (NCRR)
      -   Phase 1/Phase 2   NCT00000102   United States;
Pioglitazone   
   Radboud University
      2005   -   NCT00151710   Netherlands;
Prednisolone   
   Haukeland University Hospital
      2014   Phase 2   EUCTR2011-005822-23-SE   Norway;Sweden;
      2012   -   EUCTR2011-005822-23-NO   Norway;
Prednisolone 1mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 2,5 mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5 mg Tablets   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5mg Tablet   
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisone   
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China;
SPR001   
   Spruce Biosciences
      2018   Phase 2   NCT03687242   United States;
      2017   Phase 2   NCT03257462   United States;
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Spruce Biosciences, Inc.
      2021   Phase 2   EUCTR2019-004765-40-PL   Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-004764-22-PL   Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004765-40-SE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004765-40-NL   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004765-40-DK   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004765-40-DE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004764-22-SE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004764-22-NL   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004764-22-GB   Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004764-22-DK   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004764-22-DE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Standard Care   
   Diurnal Limited
      2018   Phase 3   NCT03532022   United States;
Standard glucocorticoid therapy   
   Diurnal Limited
      2016   Phase 3   NCT02716818   United States;
   University of Minnesota
      2019   Phase 1   NCT03718234   United States;
Subcutaneous hydrocortisone   
   University of Minnesota
      2019   Phase 1   NCT03718234   United States;
Tildacerfont   
   Spruce Biosciences
      2021   Phase 2   NCT05128942   -
      2020   Phase 2   NCT04544410   Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;
      2020   Phase 2   NCT04457336   Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;